أليندرونات تيڤع ٧٠ ملغ

المعلومات الرئيسية

  • اسم تجاري:
  • أليندرونات تيڤع ٧٠ ملغ
  • الشكل الصيدلاني:
  • TABLETS
  • طريقة التعاطي:
  • PER OS
  • يسخدم من اجل:
  • البشر
  • نوع الدواء:
  • المخدرات الوباتشيك
  • المصنعة من قبل:
  • TEVA PHARMACEUTICAL INDUSTRIES LTD

المستندات

الأقلمة

  • متاح في:
  • أليندرونات تيڤع ٧٠ ملغ
    إسرائيل
  • اللغة:
  • العربية

معلومات العلاجية

  • المجموعة العلاجية:
  • ALENDRONIC ACID
  • الخصائص العلاجية:
  • For the treatment of osteoporosis in postmenopausal women to prevent fractures, including those of the hip and spine (vertebral compression fractures).Treatment to increase bone mass in men with osteoporosis.

معلومات أخرى

الحالة

  • المصدر:
  • Ministry of Health - State of Israel
  • تخويل:
  • 130673089300
  • تاريخ الترخيص:
  • 01-03-2009
  • اخر تحديث:
  • 09-08-2016

معلومات المرضى النشرة

!" #

Alendronate           70 mg

as sodium monohydrate)

Microcrystalline cellulose, croscarmellose sodium, magnesium stearate.  

"

" ! $

& % ! & & ! &

" #

"  

& )

" % " %

"   '     &

& )

" %

& ' % ! ( $

" &

& % %

& % % "

" & )

& ' & # ( % &

'  

" % & '

" %    

" +

" &

,,,,, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,

,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,

& !

& ( & & )

&   % !

$ / $ 0* 1$

19-9-2018

National dietary survey in 2012‐2016 on the general population aged 1‐79 years in the Netherlands

National dietary survey in 2012‐2016 on the general population aged 1‐79 years in the Netherlands

Published on: Tue, 18 Sep 2018 00:00:00 +0200 During the years 2012‐2016, the Dutch National Food Consumption survey was conducted in the Netherlands. For the survey, a random sample was drawn from consumer panels stratified by age and gender and maintained representative to the population with regard to region, address density and educational level. Complete results were obtained for 4,313 persons (response rate 65%); including toddlers, children, adolescents, adults and elderly. Pregnant or lactating ...

Europe - EFSA - European Food Safety Authority Publications

18-7-2018

Sodium glucose co-transporter 2 inhibitors

Sodium glucose co-transporter 2 inhibitors

Safety advisory - diabetic ketoacidosis and surgical procedures

Therapeutic Goods Administration - Australia

2-7-2018

€ 70 miljoen voor uitkomstgerichte zorg

€ 70 miljoen voor uitkomstgerichte zorg

Minister Bruno Bruins voor Medische Zorg en Sport investeert € 70 miljoen in uitkomstgerichte zorg (2018-2022). Uitgangspunt is dat een goede behandeling moet passen bij de persoonlijke situatie van de patiënt. En dat kan voor iedereen anders zijn. Arts en patiënt moeten samen kunnen beslissen wat voor die persoon de beste behandeling is en waar de kwaliteit het beste is. Om die ontwikkeling te stimuleren worden de komende jaren stappen gezet.

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

11-7-2018

Vantavo (Merck Sharp and Dohme B.V.)

Vantavo (Merck Sharp and Dohme B.V.)

Vantavo (Active substance: alendronic acid / colecalciferol) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)4511 of Wed, 11 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/1180/T/30

Europe -DG Health and Food Safety

1-6-2018

Valproate

Valproate

Valproate (Active substance: medicinal products containing substances related to valproate (sodium valproate, valproic acid, valproate semisodium, valpromide, valproate magnesium)) - Community Referrals - Art 31 - Commission Decision (2018)3623 of Fri, 01 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/A-31/1454

Europe -DG Health and Food Safety